Home » Stocks » ZOM

Zomedica Corp. (ZOM)

Stock Price: $1.02 USD 0.06 (6.67%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 846.13M
Revenue (ttm) n/a
Net Income (ttm) -15.60M
Shares Out 550.54M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $1.02
Previous Close $0.96
Change ($) 0.06
Change (%) 6.67%
Day's Open 1.08
Day's Range 1.00 - 1.09
Day's Volume 135,715,450
52-Week Range 0.07 - 1.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 11 hours ago

The veterinary technology specialist is strengthening its distribution network.

GlobeNewsWire - 19 hours ago

ANN ARBOR, Mich., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica”), a veterinary health company creating point-of-care diagnostics products for dogs and cats,...

InvestorPlace - 4 days ago

Zomedica Pharmaceuticals is likely a pump-and-dump. Don't get caught holding the bag when ZOM stock crashes back to under $1 per share.

The Motley Fool - 6 days ago

Investors are intrigued by the popular penny stock's new razor and blade strategy.

InvestorPlace - 6 days ago

Zomedica shares are surging after the company updated investors on a warrant-redemption cash influx and news that its end-of-March product rollout is on track. Pet-related stocks are hot and Z...

GlobeNewsWire - 1 week ago

ANN ARBOR, Mich., Jan. 18, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products f...

InvestorPlace - 1 week ago

Even with the company addressing a potentially hyper-growth market, the price action of ZOM stock is just too frothy. The post Expect This Pullback in High-Flying Zomedica Pharmaceuticals Stoc...

The Motley Fool - 1 week ago

Traders are bailing out of the penny stock after learning that a celebrity's "endorsement" was not all it appeared to be.

The Motley Fool - 1 week ago

A booming market for pet care could push this soaring stock even higher.

Other stocks mentioned: QRVO
The Motley Fool - 1 week ago

Here's why you may want to consider selling your shares now.

Seeking Alpha - 1 week ago

Zomedica is a development-stage company that focuses on the unmet diagnostic and therapeutic treatment needs of clinical veterinarians. The company's first product - TRUFORMA - is an innovativ...

InvestorPlace - 2 weeks ago

ZOM stock continues to rocket higher. Here's what you should know about the red-hot pet care play Zomedica now.

The Motley Fool - 2 weeks ago

The pet care company's new diagnostic platform could be a game changer.

Benzinga - 2 weeks ago

A penny stock popped Monday and “Tiger King” star Carole Baskin could be the reason. What Happened: A video on YouTube shows Baskin discussing Zomedica Corp (NYSE: ZOM) and the company's upcom...

InvestorPlace - 2 weeks ago

Zomedica's TRUFORMA platform could disrupt the $2.8 billion vet diagnostics market and propel ZOM stock above $3. The post Here's Why Red-Hot ZOM Stock Could Soar Another 200% appeared first o...

The Motley Fool - 2 weeks ago

Investors are excited about the pet care company's upcoming product launch.

InvestorPlace - 2 weeks ago

Zomedica Pharmaceuticals is riding the wave of rising pet care spending. What's got tails wagging this morning about ZOM stock?

GlobeNewsWire - 3 weeks ago

ANN ARBOR, Mich., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products f...

GlobeNewsWire - 1 month ago

Progress Continuing Toward Commercialization of TRUFORMA™ Progress Continuing Toward Commercialization of TRUFORMA™

GlobeNewsWire - 1 month ago

ANN ARBOR, Mich., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products f...

Zacks Investment Research - 1 month ago

Zomedica (ZOM) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Insider Monkey - 1 month ago

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. A...

Pulse2 - 2 months ago

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) jumped 18.27% today. Here's an explanation of why that happened.

Pulse2 - 2 months ago

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) has increased by 18.38% today. What caused the stock price to increase?

InvestorPlace - 2 months ago

We all want the best for our furry friends. That's why ZOM stock is surging higher on positive news from Zomedica Pharmaceuticals.

GlobeNewsWire - 2 months ago

Certain assays under development are believed to be the first ever for use at the point-of-care and the first ever available in veterinary medicine Certain assays under development are believe...

GlobeNewsWire - 2 months ago

ANN ARBOR, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or “Company”) today reported consolidated financial results for the third quarter ended Septe...

GlobeNewsWire - 2 months ago

ANN ARBOR, Mich., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) announced today that the following letter from Robert Cohen, Interim Chief Executive Officer, has been m...

GlobeNewsWire - 3 months ago

ANN ARBOR, Mich., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (formerly Zomedica Pharmaceuticals Corp.) (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company cre...

GlobeNewsWire - 4 months ago

ANN ARBOR, Mich., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care dia...

GlobeNewsWire - 4 months ago

ANN ARBOR, Mich., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced today that its proxy solicitor, Alliance Advisors, mailed the following let...

GlobeNewsWire - 4 months ago

ANN ARBOR, Mich., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), a veterinary health company creating point-of-care diagnostics products for companio...

GlobeNewsWire - 4 months ago

Three new assays to be added to the five assays currently under development Three new assays to be added to the five assays currently under development

GlobeNewsWire - 4 months ago

ANN ARBOR, Mich., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced today that the following letter from Robert Cohen, Interim Chief Executive O...

GlobeNewsWire - 5 months ago

ANN ARBOR, Mich., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (“Zomedica” or “Company”), a veterinary health company, today reported consolidated f...

GlobeNewsWire - 5 months ago

ANN ARBOR, Mich., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (“Zomedica”) (NYSE American: ZOM), a veterinary health company, announced that Robert Cohen, Interim Chief ...

InvestorPlace - 5 months ago

Penny stocks will always be risky. That said, with the huge disconnect we’re seeing in the markets, now may be a time to gamble.

Other stocks mentioned: IDEX, SOLO, TDRYD, TNXP, XSPA
Zacks Investment Research - 5 months ago

Zomedica (ZOM) will provide an update on Truforma, its inaugural point-of-care diagnostic biosensor platform, when it reports second-quarter 2020 results

Zacks Investment Research - 5 months ago

Zomedica Pharmaceuticals Corp. (ZOM) closed the most recent trading day at $0.16, moving +0.57% from the previous trading session.

GlobeNewsWire - 5 months ago

ANN ARBOR, Mich., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (“Zomedica”) (NYSE American: ZOM) (TSX-V: ZOM), a veterinary health company, announced that Shameze Rampert...

Zacks Investment Research - 5 months ago

Zomedica Pharmaceuticals Corp. (ZOM) closed at $0.16 in the latest trading session, marking a -0.3% move from the prior day.

GlobeNewsWire - 6 months ago

Permits Validation and Pilot Program Progress During COVID-19 Restrictions Permits Validation and Pilot Program Progress During COVID-19 Restrictions

Zacks Investment Research - 6 months ago

Zomedica Pharmaceuticals Corp. (ZOM) closed at $0.16 in the latest trading session, marking a +1.31% move from the prior day.

GlobeNewsWire - 6 months ago

ANN ARBOR, Mich., July 07, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the cl...

InvestorPlace - 6 months ago

The market might be facing turbulence, but Louis Navellier says there are three sectors that should treat investors well regardless   Do you know where the term “dog days of summer” comes from...

Other stocks mentioned: IBB, ZM
GlobeNewsWire - 6 months ago

ANN ARBOR, Mich., July 01, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the p...

GlobeNewsWire - 6 months ago

ANN ARBOR, Mich., July 01, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary diagnostic company, announced today that ...

Zacks Investment Research - 6 months ago

Zomedica (ZOM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

GlobeNewsWire - 7 months ago

Moves Closer to Development Completion of Its Novel Point-of-Care Diagnostic Platform Moves Closer to Development Completion of Its Novel Point-of-Care Diagnostic Platform

GlobeNewsWire - 7 months ago

ANN ARBOR, Mich., May 29, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the clo...

About ZOM

Zomedica, a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism ... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
2015
Stock Exchange
NYSEAMERICAN
Ticker Symbol
ZOM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Zomedica stock is "Buy" and the 12-month stock price forecast is 0.50.

Price Target
$0.50
Analyst Consensus: Buy